Fig. 1From: Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and survivalThe number of patients in each subgroup is presented as well as the 5-year survival rate [%]. a Significant differences in survival were documented with respect to three groups of Masaoka-Koga stages. Stage III patients had a lower survival than patients with stage IV. b Survival curves with respect to the proposed IASLC/ITMIG stages showed also significant differencesBack to article page